A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

Authors


  • S.F. designed research, contributed patients, performed research, analyzed data, and wrote the paper; G.G.-M., E.J., F.R., G.B., Z.E., and J.C. contributed patients; V.G. designed the study and analyzed data; A.L.B. and M.K. performed research; H.M.K. designed the study, performed research, and contributed patients.

Abstract

BACKGROUND:

Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited.

METHODS:

The goal of this study was to evaluate the activity and safety of 2 different doses (15 mg/m2 vs 30 mg/m2 daily × 5 days) of intravenous clofarabine in patients with higher-risk MDS. Fifty-eight patients with a median age of 68 years (range, 25-89) including 15 patients (28%) with secondary MDS and 35 patients (60%) who received prior DNA methyltransferase (DNMT) inhibitors were adaptively randomized between the 2 dose cohorts.

RESULTS:

The overall response rate (ORR; based on a modification of International Working Group criteria) was 36% including 26% with complete remission (CR) (ORR, 41% at 15 mg/m2 and 29% at 30 mg/m2). Responses were lower in patients who failed DNMT inhibitors (ORR, 17%; CR rate, 14%). The 8-week mortality rate was 19%. Median survival was 7.4 months for all patients, 13.4 months for responders, and 21.7 months for complete responders. Some adverse events, particularly hepatic and renal, were more severe (grade >2) in patients randomized to 30 mg/m2 of clofarabine. Myelosuppression and infectious complications were frequent.

CONCLUSIONS:

Both the lower and higher doses of clofarabine have comparable clinical activity, but the lower dose appeared less toxic. If these results are confirmed, lower doses of clofarabine, possibly in alternative schedules, should be pursued. Cancer 2012;. © 2011 American Cancer Society.

Ancillary